Because conventional methods cannot downregulate the protein level of STAT3, Hong et al. used a 2.5-generation cEt-ASO (AZD9150) to suppress STAT3 expression, resulting in antitumor activity in lymphoma and lung cancer models 217. The gene discussed is STAT3; the disease is lung cancer.